Table 3. Primary Analysis Resultsa.
| Outcome | HR (95% CI) | RD (95% CI) at 1 y | RD (95% CI) at 2 y |
|---|---|---|---|
| Overall mortality | 1.15 (0.97 to 1.34) | 0.008 (−0.001 to 0.017) | 0.005 (−0.006 to 0.016) |
| MI | 1.11 (0.77 to 1.45) | −0.002 (−0.004 to 0.001) | −0.0004 (−0.005 to 0.005) |
| Hospitalization for CHF | 0.93 (0.75 to 1.11) | −0.002 (−0.006 to 0.003) | −0.005 (−0.011 to 0.001) |
| Stroke or CVA | 1.30 (0.81 to 1.78) | 0.004 (−0.002 to 0.009) | 0.004 (−0.003 to 0.011) |
| CVD mortality | 1.26 (0.86 to 1.66) | 0.009 (−0.001 to 0.020) | 0.003 (−0.008 to 0.014) |
Abbreviations: CHF, congestive heart failure; CVA, cerebrovascular accident; CVD, cardiovascular disease; HR, hazard ratio; MI, myocardial infarction; RD, risk difference.
a
Data are given from the primary analysis for each outcome. The reference exposure regimen is continuous exposure to human insulin therapy.